| Phenotype | eGFR<60 mL/min/1.73m2 used to define CKD (stage 3 or greater) |
| Sample Ancestry | African unspecified |
| Total number | 14,544 individuals |
| Detailed numbers |
4,268 cases (29.35%)
10,276 controls
0.61% Male samples
|
| Age of Study Participants | Mean : 61.0 years |
| Number of Cohort(s) | 7 |
| Cohort Short Name | Cohort Full Name | Previous/other/additional names (e.g. sub-cohorts) |
|---|---|---|
| BioMe | BioMe® BioBank Program (Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai) | BioMe Biobank (BMBB), MT. SINAI BioMe Biobank Platform (IMP), Charles R Bronfman Institute for Personalized Medicine - IPM / BioBank Genome Wide Association Study of Cardiovascular, Renal and Metabolic Phenotypes (IPM), Charles R Bronfman Institute for Personalized Medicine - IPM / BioBank Genome Wide Association Study of Cardiovascular, Renal and Metabolic Phenotypes I (IPM I), Charles R Bronfman Institute for Personalized Medicine - IPM / BioBank Genome Wide Association Study of Cardiovascular, Renal and Metabolic Phenotypes II (IPM II), IPM_EA_Affy, IPM_EA_Illu, Mount Sinai BioMe BioBank (Mount Sinai) |
| eMERGE | Medical Records and Genomics study | — |
| GenHAT | Genetics of Hypertension Associated Treatment | — |
| HYPERGEN | Hypertension Genetic Epidemiology Network | — |
| REGARDS | Reasons for Geographic and Racial Differences in Stroke | — |
| UKB | UK Biobank | — |
| WPC | Warfarin Pharmacogenomics Cohort | — |